BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring
- 11 February 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (5) , 1964-1978
Abstract
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A−B−C system characterized by a para-substituted central aromatic core connected to an imidazo[4,5]pyridin-2-one scaffold and a substituted urea linker. Here, we present a new series of BRAF inhibitors in which the central phenyl ring connects to the hinge binder and substrate pocket of BRAF with a meta-substitution pattern. The optimization of this new scaffold led to the development of low-nanomolar inhibitors that permits the use of a wider range of linkers and terminal C rings while enhancing the selectivity for the BRAF enzyme in comparison to the para series.Keywords
This publication has 23 references indexed in Scilit:
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancerOncogene, 2007
- Melanoma biology and new targeted therapyNature, 2007
- Recent Advances in the Research and Development of RAF Kinase InhibitorsCurrent Topics in Medicinal Chemistry, 2006
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- B-RAF is a therapeutic target in melanomaOncogene, 2004
- V599EB-RAF is an Oncogene in MelanocytesCancer Research, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Design and Discovery of Small Molecules Targeting Raf-1 KinaseCurrent Pharmaceutical Design, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001